HKSTP
Hong Kong Science and Technology Parks Corporation (HKSTP) today held its first-ever hybrid Elevator Pitch Competition (EPiC), with over 600 startups from Hong Kong and around the world joining the annual signature event. HKSTP is approaching 20 years of leading innovation in Hong Kong with the return of EPiC 2021 to its iconic home at sky100 at the top of the International Commerce Centre in West Kowloon to re-create a genuine 60-second elevator pitch experience.
In its sixth year, the annual EPiC event in hybrid format for the first time, allowed overseas innovators to go beyond geographical boundaries and join the virtual EPiC event and journey live. This year’s event surpassed all expectations, attracting over 600 entries from 40 countries and cities across five continents. A total of over 160 contestants entered the semi-final round, with nearly 60% from overseas.
This year’s overall EPiC Champion, Winner of Green Tech & Construction Tech Category, as well as the “My Favourite Pitcher” award belong to Hong Kong-based archiREEF. The Greentech startup beat all other finalists with its innovative climate solutions and eco-engineering technology for ocean ecosystems restoration. The company combines expertise in marine biology and the latest technologies in 3D printing techniques and material science to create artificial habitats that are best suited for different marine life anywhere in the world.
The other three tech category winners included: FinTech Winner, Hong Kong-based Wizpresso; Health Technology Winner, Hong Kong-based PointFit Technology, and Smart City Winner, Israel-based Intelligent Traffic Control (ITC). All EPiC entries this year were focused on one of four key themes: FinTech, Green Tech & Construction Tech, Health Technology, and Smart City.
Albert Wong, CEO at HKSTP, said: “The return of our flagship pitching and investment event EPiC 2021 at the iconic sky100 is the ideal platform to lead into our 20th year, while the record participation is a showcase of the city’s growing entrepreneurial strength and world-class I&T potential. The EPiC week of activities provides a unique borderless experience that educates and connects innovators around the world with insights to sharpen entrepreneurial skills and deepen knowledge on the thriving Hong Kong and Greater Bay Area market. EPiC is where we unlock opportunities, where innovation begins and where talent flourishes as pioneers and innovators connect in a genuine haven of global innovation and investment.”
EPiC is a week-long platform generating opportunities not only for the winners but for all participants. Global and local entrepreneurs have interacted with active investors and innovation ecosystem leaders at this year’s EPiC competition. Meanwhile, physical and virtual guests from various industries and territories explored a wealth of GBA and international business partnership, as well as investment opportunities. The competition leads on to the Investment & Business Matching from November 8-12 and finally the Investment Conference on November 12, to complete a week of immersion into HKSTP’s world-class I&T ecosystem.
Since its inception in 2016, HKSTP’s EPiC has drawn a huge number of international participants to grasp a one-minute elevator pitch opportunity to some of the most demanding investors and judges in Hong Kong. The top ten finalists were given another opportunity to face the judges in a three-minute live pitch and two-minute Q&A. The overall champion took away a cash prize of US$100,000, while each of the category winners received a cash prize of US$10,000 and all ten finalists won US$6,000 each.
List of Winners:
Award |
Company |
Market |
Overall Champion and Green Tech & Construction Tech Category Winner |
archiREEF |
Hong Kong |
FinTech Category Winner |
Wizpresso |
Hong Kong |
Health Technology Category Winner |
PointFit Technology |
Hong Kong |
Smart City Category Winner |
Intelligent Traffic Control (ITC) |
Israel |
My Favourite Pitcher |
archiREEF |
Hong Kong |
Other Top 10 Finalists: |
Aortyx |
Spain |
|
Clear Robotics |
Hong Kong |
|
Novai |
UK |
|
Papkot |
France |
|
TicTAP – Simply Connect |
Spain |
|
Vista InnoTech |
Hong Kong |
About Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) has for 20 continuous years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to three unicorns and Hong Kong’s leading R&D hub with over 11,000 research professionals and over 1,000 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.
Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of the Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long. The three InnoParks are realizing a vision of re-industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.
Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.
More information about HKSTP is available at www.hkstp.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20211105005610/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom